Gliclazid Arcana

Quick links

Choose a section

Quick links to important sections

Advertisements

Gliclazid Arcana

Advertisements
Advertisements

Overview of Gliclazid Arcana

What is Gliclazid Arcana?

Gliclazid Arcana is an oral medication used to help control blood sugar levels in adults with type 2 diabetes mellitus. It belongs to a group of medicines known as sulfonylureas.

Mechanism of Action

The medication works by stimulating the pancreas to produce more insulin. Insulin is the hormone responsible for moving sugar from the bloodstream into the body's cells, where it is used for energy. By increasing insulin secretion, the medication helps to lower blood glucose levels when they are too high.

Therapeutic Role

In type 2 diabetes, the body either does not produce enough insulin or cannot use the insulin it makes effectively. This leads to elevated blood sugar levels, which can cause long-term health complications if left unmanaged. Gliclazid Arcana is typically used in conjunction with specific dietary changes and physical exercise when these lifestyle measures alone are not sufficient to maintain healthy blood glucose targets.

Key Characteristics

  • Class: Sulfonylurea.
  • Formulation: It is often available in modified-release formulations, which allow the active ingredient to be released gradually into the system over a longer period.
  • Indication: Specifically indicated for type 2 diabetes; it is not used for the treatment of type 1 diabetes.

Regulatory References

  1. PubMed ID: 31085002
Advertisements

What side effects are possible with Gliclazid Arcana?

Possible Side Effects and Safety Information

The safety profile of Gliclazide, the active ingredient in Gliclazid Arcana, is officially documented by government regulatory agencies based on clinical and post-marketing experience. Adverse reactions are classified by the frequency of their occurrence, and key effects are grouped by the affected physiological system.


Frequency-Classified Adverse Reactions

The most frequent adverse reaction is hypoglycaemia (low blood sugar), which is officially classified as a common event (ge 1/100 to <1/10). Hypoglycaemia is an expected effect for agents in the sulfonylurea class. Uncommon (ge 1/1,000 to <1/100) effects include transient visual disturbances at the start of treatment and gastrointestinal disturbances such as abdominal pain, nausea, and vomiting. Rare effects include blood and lymphatic system disorders like agranulocytosis and anaemia.


Systemic Safety and Serious Reactions

Adverse effects are documented across several System-Organ Classes (SOC), including Metabolism and nutrition disorders, Gastrointestinal disorders, Hepatobiliary disorders, and Blood and lymphatic system disorders. Serious adverse reactions listed in regulatory labeling include severe hypoglycaemia, severe hepatic dysfunction (hepatitis, jaundice), and blood dyscrasias (e.g., aplastic anaemia). Most blood and hepatic reactions are documented as generally reversible upon discontinuation.


Safety Considerations and Restrictions

Official safety statements explicitly note an increased susceptibility to hypoglycaemia in older adults and individuals who are malnourished. Use of Gliclazide is formally contraindicated in conditions such as severe hepatic or renal impairment, diabetic pre-coma or coma, and severe infection or trauma. Patients with G6PD deficiency should be managed with caution due to the documented risk of haemolytic anaemia.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The most prominent and officially documented manifestation of Gliclazide overdose is profound and prolonged hypoglycaemia, or critically low blood sugar, due to excessive stimulation of insulin release. Symptoms may include a broad range of neurological and physical signs, such as headache, confusion, agitation, lassitude, speech disorders, tremor, and signs of adrenergic counter-regulation like sweating and tachycardia.

Overdose may escalate to severe hypoglycaemia, which carries the documented risk of hypoglycaemic coma, permanent neurological damage, or a fatal outcome if left uncorrected. Official regulatory information identifies that specific populations, including elderly subjects and patients with impaired hepatic or renal function, are particularly susceptible to severe and prolonged reactions.

Required Emergency Actions

Regulatory agencies mandate that immediate medical treatment or hospitalisation is required if the hypoglycaemic episode is classified as severe or prolonged, or if the patient becomes unconscious and cannot be roused. The necessary therapeutic intervention is the administration of carbohydrates or glucose. For severe cases, procedural steps involve intravenous glucose administration and prolonged hospital monitoring over several days.

Advertisements

Therapeutic Uses of Gliclazid Arcana

What Gliclazid Arcana Treats: Main Uses and Benefits

Gliclazid Arcana is commonly used for the long-term, systematic management of Type 2 diabetes mellitus in adults. The medication is generally applied in contexts where additional symptomatic support is relevant when initial lifestyle modifications do not reach treatment goals.

Gliclazide is used for managing conditions characterized by persistent hyperglycemia and is relevant for patients requiring supportive management beyond first-line oral agents. The core therapeutic indications are addressing chronic high blood sugar, assisting with suboptimal glycemic control, and providing support during treatment intensification.

“The use of Gliclazide is aligned with the need to support patients in managing long-term metabolic stability and seeking improved comfort.”

This agent is commonly used when groups of symptoms, specifically fluctuating and high blood sugar levels, are associated with noticeable physiological strain despite existing therapy. It is relevant when short-term symptom stabilization is important, as it may contribute to a lower HbA1c result. This application contributes to easing the overall symptom load associated with metabolic imbalance, and helps improve day-to-day comfort during symptomatic periods. It is considered relevant for patients with residual beta-cell function.


Quick Fact: Management of Hyperglycemia Gliclazide supports the management of elevated fasting and postprandial glucose levels, and may assist with maintaining a more stable range throughout the day.

Advertisements

Eligibility and Restrictions for Use

Gliclazid Arcana (Gliclazide) is an approved prescription medication restricted to the adult population diagnosed with Type 2 diabetes mellitus. Use is officially permitted only as an adjunct to diet and exercise.

The medicine must not be used in several patient groups, as formally documented in regulatory labeling. This includes patients with Type 1 diabetes mellitus or acute diabetic states such as diabetic ketoacidosis or diabetic coma. Use is also strictly contraindicated in cases of severe hepatic insufficiency or severe renal insufficiency.

Furthermore, the medication is contraindicated during pregnancy and lactation. A known hypersensitivity to Gliclazide, other sulfonylureas, or sulfonamides also prohibits use. Use is also formally contraindicated when receiving concurrent Miconazole treatment.

The medication is not recommended for children and adolescents because safety and effectiveness have not been established in the pediatric population. Individuals with irregular food intake or malnutrition require special precautions and careful monitoring. Use is also temporarily contraindicated during physiological stress conditions such as serious infection or trauma.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section details officially documented interaction patterns for Gliclazid Arcana (Gliclazide), based on regulatory prescribing information. The interaction profile is structured around combinations that may amplify the drug’s effects, reduce its efficacy, or are formally prohibited.


Official Administration Restrictions

Co-administration of Miconazole (systemic or oromucosal gel) is formally contraindicated due to a severe potentiation of the hypoglycaemic action. Regulatory documents also advise against the use of alcohol or medicines containing alcohol, as this may increase the hypoglycaemic reaction risk by inhibiting the body's compensatory mechanisms.


Documented Pharmacological Interactions

Interaction Type Examples of Interacting Substances/Classes
Increased Hypoglycaemic Effect (Potentiation) Other Antidiabetic Agents, Fluconazole, Clarithromycin, ACE Inhibitors, Beta-blockers, Phenylbutazone, MAOIs.
Reduced Therapeutic Efficacy (Hyperglycaemic Risk) Glucocorticoids, Danazol, Beta-2 Agonists (e.g., Ritodrine, Salbutamol, Terbutaline), St. John's Wort.

Interactions that reduce efficacy include co-administration with St. John's Wort, which is documented to reduce Gliclazide exposure by increasing clearance, potentially leading to a loss of glycemic control. Conversely, substances like Phenylbutazone may increase the drug's effect by displacing it from plasma proteins.


Population-Specific Interaction Notes

Official prescribing information notes that a hypoglycaemic episode may be prolonged in the context of Hepatic Insufficiency or Severe Renal Failure due to altered pharmacokinetics/pharmacodynamics. Additionally, the risk of unstable blood glucose (dysglycemia) is heightened for elderly patients when Gliclazide is co-administered with fluoroquinolones.

Advertisements

Mechanism of Action

How Gliclazid Arcana Works

Modulation of K^+ ATP Channels and Insulin Release

Gliclazide's primary mechanism involves binding to the Sulfonylurea Receptor 1 ( SUR1) subunit of the K^+ ATP channel on the pancreatic beta-cell membrane, causing the channel to close. This closure initiates a cellular cascade: K^+ retention leads to membrane depolarization, triggering the influx of calcium ( Ca^2+) ions, which ultimately signals the exocytosis and release of stored Insulin granules. This action increases the systemic availability of insulin, which subsequently influences the cellular movement of glucose out of the circulation.


️ Extrapancreatic Vascular Oxidative Protection

The molecule's chemical structure allows it to act as a free radical scavenger and antioxidant. This mechanism involves the reduction of oxidative stress, affecting the processes that determine endothelial integrity. Furthermore, Gliclazide modulates platelet reactivity and promotes fibrinolytic activity, influencing hemorheological properties in the microvasculature independently of its primary insulin-stimulating action.

Advertisements

Dosage and Administration Information

How Gliclazid Arcana Is Used: Official Usage Principles

Gliclazid Arcana, containing the active substance Gliclazide, is administered via the oral route as a modified-release (MR) tablet. The drug is prescribed for once-daily use, which is critical for maintaining the intended consistent release of the active substance over a prolonged period.

Dosing Regimens and Administration

The officially approved adult dosing range for Gliclazide MR is between 30 mg and 120 mg daily, taken as a single dose. Treatment typically begins with a starting dose of 30 mg once per day. The dose is then adjusted based on the patient's metabolic response, which is evaluated by monitoring blood glucose and HbA1c levels. The maximum recommended daily dose is 120 mg.

Administration Requirements

Feature Guideline/Rule
Timing Must be taken as a single daily dose at the time of breakfast or the first main meal of the day.
Handling Tablets must be swallowed whole with water. They must not be chewed or crushed to maintain the modified-release action.
Missed Dose If a dose is missed, the patient should skip it and take the next dose at the usual time; do not take a double dose to compensate.

Titration Protocol and Specific Populations

Regulatory protocols stipulate that the interval between any dose increment should generally be at least one month. The same dosing regimen is used for older adults and patients with mild to moderate renal insufficiency, but careful monitoring is required. For individuals identified as having a higher risk of hypoglycemia, the official guidelines recommend using the minimum daily starting dose of 30 mg.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Gliclazid Arcana

Research examining the clinical evaluation of Gliclazide for conditions associated with high blood sugar in Type 2 Diabetes has involved Randomized Controlled Trials (RCTs) and larger, multi-year observational studies. These studies focused on outcomes such as changes in specific biomarkers and the incidence of clinical events.


Evidence for Glycemic Management in Type 2 Diabetes

The key biomarker monitored in this research was Glycated Hemoglobin ( HbA1 c), which indicates average blood sugar levels. Studies monitored and reported changes in this biomarker, along with microvascular and macrovascular events (such as issues affecting the eyes, kidneys, and circulatory system). The research primarily included adults and those whose previous therapies were not meeting study goals.


Comparative Research Against Other Diabetes Medicines

Research examined Gliclazide in direct comparison to other medicines, particularly those belonging to the same pharmacological class, known as sulfonylureas. Comparative studies specifically evaluated differences in the rate of hypoglycemia (abnormally low blood sugar) observed between agents. The research also monitored and reported comparative changes in HbA1 c across Gliclazide and the other comparators.


Long-Term Studies and Durability of Response

Long-term research was designed to observe extended outcomes and track clinical events over many years. Research provided insight into the stability of blood sugar control. However, few dedicated trials were designed specifically to independently test the medicine’s long-term outcomes on events like heart attack and stroke. The trial design often limits the ability to attribute these results solely to the single agent, as it was often used as part of a complex, intensive treatment plan.


Evidence in Specific Patient Populations

Research has examined Gliclazide in specific patient groups, including older adults, where outcomes related to acute changes, such as hypoglycemia, were of particular interest. However, data for certain groups remain limited. For instance, there is insufficient information for long-term outcomes in specific kidney populations or in relation to children.


What is Still Uncertain About the Research

The certainty of the evidence is affected by several research limitations that have been reported. These include the lack of dedicated studies designed solely to establish Gliclazide’s independent effects on major cardiovascular events. Additionally, evidence quality varies across studies, and comparative evidence is lacking against many of the newer classes of oral diabetes medicines.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Gliclazid Arcana (FAQ)

Q: Is Gliclazid Arcana the same as regular Gliclazide?

Gliclazid Arcana contains the active substance Gliclazide. It is generally supplied as a modified-release (MR) formulation, which is designed to release the medicine gradually and consistently over an extended period. This MR design differentiates it from immediate-release (non-MR) forms, which have a different administration regimen.


Q: What makes Gliclazid Arcana different from Metformin?

Gliclazid Arcana belongs to the sulfonylurea class, which acts primarily by stimulating the pancreas to release its own insulin. Metformin, on the other hand, belongs to a different pharmacological class and works through different mechanisms within the body to lower blood sugar. Official regulatory documents define them as distinct types of anti-diabetic agents.


Q: Does Gliclazid Arcana cause weight gain?

Clinical studies focusing on the modified-release formulation have indicated that body weight typically remains stable during use. However, regulatory documents note that as a class of drug (sulfonylureas), there is a known potential for changes in weight.


Q: Is feeling dizzy a common side effect of Gliclazid Arcana?

Dizziness is a documented manifestation of hypoglycemia (low blood sugar), which is the most frequent adverse reaction listed in official product information. This effect is a documented potential outcome, as the medicine works to lower blood sugar. Other documented signs of hypoglycemia can include sweating, headache, and confusion.


Q: Can Gliclazid Arcana affect my liver?

Regulatory documents list potential effects on the liver, including serious adverse reactions such as severe hepatic dysfunction (hepatitis or jaundice). Use is formally contraindicated in patients with severe hepatic impairment. Official documents indicate these effects are generally reversible upon discontinuation of the medicine.


Q: Can Gliclazid Arcana interact with common pain relievers like ibuprofen?

Pain relievers that belong to the class of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which includes ibuprofen, may increase the hypoglycaemic effect of Gliclazid Arcana. Regulatory documents indicate this combination has the potential to increase the hypoglycaemic effect.


Q: Can Gliclazid Arcana affect my birth control pills?

Official prescribing information notes that certain hormonal substances, specifically oestrogens and progestogens found in some birth control pills, may potentially weaken the blood sugar control provided by Gliclazid Arcana. Official documents note that blood glucose monitoring may be necessary if these substances are used at the same time.


Q: Is Gliclazid Arcana widely recommended by medical guidelines?

Official research has examined Gliclazid Arcana as part of intensive treatment regimens for Type 2 diabetes. Expert consensus opinions have supported its role as a valid option for managing the condition when first-line treatment is unsuitable or not tolerated.


Q: Can Gliclazid Arcana be used for conditions other than diabetes?

Gliclazid Arcana is formally indicated only for the control of high blood sugar in adult patients diagnosed with Type 2 diabetes mellitus. Official regulatory documents restrict its use to this specific condition.


Q: Is it common to have stomach issues when starting Gliclazid Arcana?

Gastrointestinal disturbances, such as abdominal pain, nausea, and diarrhea, are documented as uncommon side effects in official safety data. Regulatory information notes that these effects are often transient and may only occur when beginning treatment.


Q: Are there certain foods or drinks I should avoid while taking Gliclazid Arcana?

Alcohol or medicines containing alcohol are officially advised against, as their use can increase the risk of low blood sugar. Official warnings also reference the importance of regular carbohydrate intake due to the risk of hypoglycemia if meals are skipped.


Q: Are herbal supplements safe to use with Gliclazid Arcana?

The herbal remedy St. John's Wort is specifically documented in regulatory warnings to reduce the body's exposure to Gliclazide, which could lead to a loss of blood sugar control. Regulatory documents advise caution regarding the potential for interactions with herbal supplements.


Q: What happens if I miss a dose of Gliclazid Arcana?

The official guideline for a missed dose is to skip that dose entirely and take the next dose at the usual scheduled time. Official guidelines stipulate not to take a double dose to compensate, as this action increases the documented risk of low blood sugar.


Q: How long does the effect of one dose of Gliclazid Arcana typically last?

The modified-release formulation is designed to release the active substance gradually and consistently over 24 hours. This pharmacological property supports its prescribed use as a once-daily medicine taken at breakfast.


Q: Where can I find official regulatory information about Gliclazid Arcana?

Official regulatory information, such as the full product monographs, is publicly available from government drug agencies globally. These sources include the FDA (DailyMed), the EMA (SmPC), Health Canada, and the MHRA (GOV.UK).


Q: What is the purpose of the slow-release (MR) form of Gliclazid Arcana?

The modified-release (MR) formulation is a specialized design that ensures the active substance is released gradually and consistently over a full 24-hour period. This mechanism allows for once-daily dosing and is designed to maintain stable blood glucose levels.


Q: Does Gliclazid Arcana need to be taken at a specific time of day?

Official administration rules specify that the tablet must be taken as a single daily dose at the time of breakfast or the first main meal of the day. This timing supports the drug's intended release profile.


Q: What should I do if I notice a rash after starting Gliclazid Arcana?

A rash is listed among the serious skin and hypersensitivity reactions documented for this medication. Official safety statements document that the emergence of a rash necessitates immediate reporting to a healthcare professional.


Q: Why do some people switch from another drug to Gliclazid Arcana?

Clinical evidence has demonstrated that Gliclazide, when compared to certain other diabetes medicines, may be associated with a lower risk of hypoglycemia and a stable body weight. These factors are often considered in clinical decision-making when a different treatment is deemed necessary.


Q: Is Gliclazid Arcana a common prescription in other countries?

Gliclazide is documented and approved for use by major government drug agencies across several continents, including the European Medicines Agency (EMA), the UK’s MHRA, Health Canada, and the Australian TGA.


Q: Are there any genetic factors that affect how Gliclazid Arcana works?

Official safety statements note that patients with G6PD deficiency (a genetic condition affecting red blood cells) require careful management. This is due to a documented risk of a specific blood disorder called haemolytic anaemia in this population.


Q: Does stress impact the effectiveness of Gliclazid Arcana?

The medication is temporarily contraindicated during periods of acute physiological stress, such as severe infection or trauma. These stress conditions can significantly affect blood sugar control and may require a temporary change in treatment, according to regulatory guidelines.


Q: What is the difference between immediate-release and modified-release Gliclazid Arcana?

The immediate-release (IR) formulation typically requires administration more than once per day. The modified-release (MR) formulation is designed for once-daily dosing and releases the active substance gradually over time, which is an intended mechanism to help reduce the risk of low blood sugar.


Q: Can Gliclazid Arcana be split in half?

Regulatory administration rules specify that the tablets must be swallowed whole with water. They must not be chewed or crushed because breaking the tablet disrupts the specialized modified-release coating. This action can disrupt the modified-release coating, which may lead to an altered and potentially rapid release of the active substance.


Q: What is the risk of overdose with Gliclazid Arcana?

Overdosage with Gliclazid Arcana is documented to result in an episode of severe hypoglycemia (abnormally low blood sugar). Official prescribing information indicates that this low blood sugar may be prolonged and requires prompt medical attention.


Q: Do people take Gliclazid Arcana for pre-diabetes?

Gliclazid Arcana is officially indicated only for the control of high blood sugar in patients diagnosed with Type 2 diabetes mellitus. Use is restricted to the adult population with this specific diagnosis.

Advertisements

How should Gliclazid Arcana be stored and disposed of?

Official Storage and Disposal Instructions

Storage and disposal of Gliclazid Arcana must follow the specific requirements outlined in regulatory labeling to maintain product stability and ensure environmental protection.

Requirement Type Official Condition
Temperature Store at a temperature not above 25°C (room temperature).
Protection Must be kept out of the sight and reach of children.
Stability The official shelf-life is 36 months when stored under the specified conditions.

No special storage conditions are required beyond respecting the maximum temperature limit. The tablets are typically supplied in a blister pack. For disposal, the medicine must not be thrown away via wastewater or household waste. Patients are instructed to ask the pharmacist how to discard unused or expired medicine to protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gliclazid Arcana found in:

A-Z Index: